Opportunity Information: Apply for PAR 14 104
Apply for PAR 14 104
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 25, 2014 and posted on Feb 25, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: State governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) County governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Independent school districts City or township governments Private institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03)" (Funding Opportunity Number PAR-14-104) was a National Institutes of Health (NIH) discretionary grant program designed to fund small, focused research projects that improve what is known about synthetic psychoactive drugs. The overall aim was to strengthen the evidence base around how these substances are used, how they work in the body and brain, what harms they cause, and what practical strategies can reduce those harms. This includes both prevention approaches and clinical responses, with explicit attention to acute care needs in emergency departments as well as longer-term treatment and recovery.
A central emphasis of the announcement was the growing public health challenge posed by synthetic psychoactive drugs, which often evolve quickly in chemical composition and can produce unpredictable and sometimes severe health effects. The FOA called for research that can clarify patterns of use and the contexts in which people are exposed to these substances, as well as studies that investigate mechanisms of action to explain why particular synthetic compounds lead to certain behavioral, neurological, cardiovascular, or psychiatric outcomes. By supporting mechanistic and health-effects research alongside prevention and treatment-oriented work, the program was positioned to help translate basic and clinical findings into real-world interventions.
The FOA also highlighted the need for better strategies to manage patients who present with synthetic drug intoxication or complications in emergency settings. This can include research that informs triage, diagnosis, and acute management, particularly when standard toxicology screens may not detect novel compounds or when clinical presentations resemble other conditions. In addition, it supported work relevant to longer-range treatment, recognizing that some synthetic drugs may contribute to ongoing substance use disorders, persistent mental health effects, or repeated healthcare utilization. The intended outcome was actionable knowledge that improves immediate care and supports sustained prevention and treatment planning.
This opportunity used the NIH R03 mechanism, which is commonly intended for smaller-scale, short-duration projects such as pilot studies, feasibility studies, secondary analyses, early-stage intervention development, or other narrowly scoped research that can generate preliminary data for future, larger studies. The award ceiling listed for this FOA was $100,000, and there was no cost-sharing or matching requirement, meaning applicants were not required to contribute non-federal funds as a condition of receiving an award.
In terms of program classification, the funding activity category was listed under Education and Health, and the CFDA number associated with the program was 93.279, which corresponds to Drug Abuse and Addiction Research Programs. The sponsoring agency was the National Institutes of Health, and the primary source for the announcement was the NIH grants page linked in the opportunity details.
Eligibility was broad and included a wide range of domestic and non-domestic applicants. Eligible applicants included state governments, local governments (such as counties, cities or townships), special district governments, public housing authorities/Indian housing authorities, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status (including those other than institutions of higher education), and for-profit organizations other than small businesses, as well as small businesses. The FOA also explicitly included additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with federally recognized tribal governments and other tribal organizations. Faith-based and community-based organizations were eligible, as were eligible agencies of the federal government. Importantly, non-U.S. entities (foreign organizations and foreign institutions) were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components as defined under NIH policy were allowed, which signals that NIH was open to international expertise and cross-border collaboration where scientifically appropriate.
The opportunity was posted and created on February 25, 2014. The original and current closing date were both May 7, 2017, and the archive date was June 7, 2017, indicating that this particular FOA is no longer active for new submissions. For administrative support, the listing provided contact points through the NIH Office of Extramural Research (OER) Webmaster, including an email for access issues and another for linking problems, reflecting the standard NIH approach of directing technical and announcement-access questions to OER support channels.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-14-104.
Which agency sponsored this funding opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
What type of grant program was this?
This was an NIH discretionary grant program using the R03 mechanism, designed to support small, focused research projects.
What was the overall goal of the program?
The program aimed to strengthen the evidence base on synthetic psychoactive drugs by improving what is known about how they are used, how they work in the body and brain, what harms they cause, and what practical strategies can reduce those harms.
What kinds of research topics did the FOA emphasize?
The FOA emphasized research on patterns and contexts of use/exposure, mechanisms of action, health effects (behavioral, neurological, cardiovascular, and psychiatric outcomes), and practical strategies for prevention and clinical response.
Did the FOA include prevention research?
Yes. The FOA explicitly included prevention approaches as part of the effort to reduce harms from synthetic psychoactive drugs.
Did the FOA include clinical and treatment-oriented research?
Yes. The FOA included clinical responses, including acute care needs in emergency departments and longer-term treatment and recovery considerations.
Why were synthetic psychoactive drugs a central emphasis of this announcement?
The FOA highlighted synthetic psychoactive drugs as a growing public health challenge because they can evolve quickly in chemical composition and may produce unpredictable and sometimes severe health effects.
What did the FOA say about emergency department (ED) needs?
The FOA highlighted the need for better strategies to manage patients presenting with synthetic drug intoxication or related complications in emergency settings, including work that can inform triage, diagnosis, and acute management.
Did the FOA address challenges with toxicology screening?
Yes. It noted that standard toxicology screens may not detect novel compounds and that clinical presentations may resemble other conditions, supporting research to improve ED decision-making under these constraints.
Was longer-term care and recovery within scope?
Yes. The FOA recognized that some synthetic drugs may contribute to ongoing substance use disorders, persistent mental health effects, or repeated healthcare utilization, and it supported work relevant to longer-range treatment and recovery planning.
What is the NIH R03 mechanism intended for?
The R03 mechanism is commonly intended for smaller-scale, short-duration projects such as pilot studies, feasibility studies, secondary analyses, early-stage intervention development, or other narrowly scoped research that can generate preliminary data for future, larger studies.
What was the award ceiling for this FOA?
The award ceiling listed for this FOA was $100,000.
Was cost-sharing or matching required?
No. There was no cost-sharing or matching requirement, meaning applicants were not required to contribute non-federal funds as a condition of receiving an award.
How was this opportunity classified in terms of funding activity?
The funding activity category was listed under Education and Health.
What CFDA number was associated with this program?
The CFDA number associated with the program was 93.279 (Drug Abuse and Addiction Research Programs).
Who was eligible to apply?
Eligibility was broad and included state governments, local governments, special district governments, public housing authorities/Indian housing authorities, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), and eligible agencies of the federal government.
Were specific institution types (such as MSIs) included as eligible applicants?
Yes. The FOA explicitly included Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Were tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments and other tribal organizations were included as eligible applicants.
Were faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations were listed as eligible.
Could non-U.S. (foreign) organizations apply?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) were eligible to apply.
Were non-U.S. components of U.S. organizations allowed?
Yes. Non-U.S. components of U.S. organizations were eligible.
Were foreign components allowed under NIH policy?
Yes. Foreign components as defined under NIH policy were allowed, indicating NIH openness to international expertise and cross-border collaboration when scientifically appropriate.
When was this opportunity posted?
The opportunity was posted (and created) on February 25, 2014.
What was the closing date for applications?
The original and current closing date were both May 7, 2017.
Is this FOA still open for new submissions?
No. The archive date was June 7, 2017, indicating that this particular FOA is no longer active for new submissions.
Where was the primary source listing for this opportunity?
The primary source for the announcement was the NIH grants page linked in the opportunity details.
Who was listed as an administrative/technical contact?
The listing provided contact points through the NIH Office of Extramural Research (OER) Webmaster, including an email for access issues and another for linking problems.
What kinds of outcomes was the FOA trying to enable?
The intended outcome was actionable knowledge that improves immediate care (including emergency management) and supports sustained prevention and treatment planning related to synthetic psychoactive drugs.
Browse more opportunities from the same category: Education Health
Next opportunity: Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01)
Previous opportunity: Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 104
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 104) also looked into and applied for these:
| Funding Opportunity |
|---|
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 104", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.